NGM Biopharmaceuticals
A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases.
Launch date
Employees
Market cap
€117m
Enterprise valuation
(€33m) (Public information from Apr 2024)
Share price
$1.54 NGM
South San Francisco California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 87.4m | 77.9m | 55.3m | 4.4m | <1m | <1m | - |
| % growth | (16 %) | (11 %) | (29 %) | (92 %) | (98 %) | 26 % | - |
| EBITDA | (104m) | (121m) | (166m) | (149m) | (154m) | (149m) | (136m) |
| % EBITDA margin | (119 %) | (155 %) | (300 %) | (3379 %) | (194073 %) | (149300 %) | - |
| Profit | (102m) | (120m) | (163m) | (142m) | (98.0m) | (94.2m) | (89.8m) |
| % profit margin | (117 %) | (155 %) | (294 %) | (3223 %) | (123644 %) | (94250 %) | - |
| EV / revenue | 22.2x | 15.7x | 6.1x | 3.5x | 1377.0x | 749.2x | - |
| EV / EBITDA | -18.7x | -10.1x | -2.0x | -0.1x | -0.7x | -0.5x | -0.9x |
| R&D budget | 164m | 162m | 181m | 118m | - | - | - |
| R&D % of revenue | 188 % | 208 % | 327 % | 2672 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$26.6m | Series A | ||
$55.4m | Series B | ||
$50.0m | Series C | ||
$106m | Series E | ||
$57.5m | Series D | ||
| N/A | N/A | IPO | |
| N/A | $125m | Post IPO Equity | |
* | $135m Valuation: $135m 30.6x EV/LTM Revenues -0.9x EV/LTM EBITDA | Acquisition | |
* | $122m | Growth Equity VC | |
| Total Funding | €380m | ||
Recent News about NGM Biopharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.